Technology
Health
Biotechnology

La Jolla Pharmaceutical

$5.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.18%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell LJPC and other stocks, options, ETFs, and crypto commission-free!

About

La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401 and LJPC-0118. Read More LJPC-501 is the proprietary formulation for angiotensin II. The LJPC-401 is the formulation of hepcidin, which is an endogenous peptide hormone and LJPC-0118 is La Jolla's investigational product for the treatment of severe malaria. The company was founded in 1989 and is headquartered in San Diego, CA.

Employees
169
Headquarters
San Diego, California
Founded
1989
Market Cap
149.01M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
591.70K
High Today
$5.72
Low Today
$5.42
Open Price
$5.54
Volume
156.93K
52 Week High
$38.39
52 Week Low
$5.01

Collections

Technology
Health
Biotechnology
Pharmaceutical
Biopharmaceutical
US
North America

News

Yahoo FinanceMay 6

La Jolla Pharmaceutical (LJPC) Reports Q1 Loss, Misses Revenue Estimates

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 10.69% and -11.75%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

110
Yahoo FinanceMay 2

La Jolla Pharmaceutical (LJPC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

The market expects La Jolla Pharmaceutical (LJPC) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2019. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

67
Simply Wall StApr 26

How Should Investors React To La Jolla Pharmaceutical Company’s (NASDAQ:LJPC) CEO Pay?

In 2012 George Tidmarsh was appointed CEO of La Jolla Pharmaceutical Company (NASDAQ:LJPC). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size.

146

Earnings

-$2.22
-$1.87
-$1.52
-$1.17
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.